Drug Profile
AAV RS1
Alternative Names: AAV2-CB-RS1; BIIB-087; rAAV hRS1; rAAV2tYF CB hRS1; Recombinant adeno associated virus vector expressing retinoshcisin; X-linked retinoschisis gene therapy-Beacon Therapeutics; XLRS gene therapy-Beacon TherapeuticsLatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; RS1 gene expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Retinoschisis
Most Recent Events
- 09 May 2023 Applied Genetic Technologies Corporation completes a phase-I/II clinical trials in Retinoschisis (In adolescents, In adults, In children) in USA (Intravitreous, Injection) (NCT02416622)
- 13 Apr 2021 TeamedOn International in-licenses AAV RS1 from Applied Genetic Technologies Corporation
- 12 Dec 2018 Applied Genetic Technologies Corporation and Biogen terminate to collaboration effective from March 2019